Susceptibility to the autoimmune thyroid diseases, Graves' disease (GD) and autoimmune hypothyroidism (AIH), depends on a complex interaction between environmental and genetic factors. The human leukocyte antigen and cytotoxic T lymphocyte-associated-4 regions appear to influence susceptibility to disease, but the effect is not major, and the other genes remain unknown. Cytokines are crucial in the regulation of immune and inflammatory responses and therefore are potential candidate genes for autoimmune thyroid disease. In a case-control study, using a unified method of genotyping, we have examined 15 polymorphisms in 9 cytokine genes in 215 patients with autoimmune thyroid disease (GD, 138; AIH, 77) and 101 normal controls.
A UTOIMMUNE THYROID disease, comprising predominantly Graves' disease (GD) and autoimmune hypothyroidism (AIH), is common, affecting approximately 2% of women and 0.2% of men. The etiology of the disease appears to involve a complex interplay of multiple genetic and environmental influences. Evidence for the role of genetic factors is shown by the increased incidence of the disease within families and by twin studies. For well defined Graves' disease, the concordance rate in monozygotic twins is reported to be 22% and 0% for dizygotic twins (1) . The human leukocyte antigen (HLA) class II genes contribute to susceptibility, and studies also suggest a role for the cytotoxic T lymphocyte-associated-4 (CTLA-4) gene (2) . However, each of these candidate genes is likely to contribute no more than 5% to the overall genetic susceptibility (3) . Other potential susceptibility loci have recently been identified by linkage analysis on chromosomes X (4), 14q31 (5) , and 20q11 (6) , but await confirmation. Candidate gene studies have proven very effective in detecting susceptibility genes for other diseases (7, 8) as well as genes important for disease progression (9) and is the strategy employed in this study.
Cytokines participate in the induction and effector phases of the immune and inflammatory response and are therefore likely to play a critical role in the development of autoimmune thyroid disease. Intrathyroidal inflammatory cells and thyroid follicular cells have been shown to produce a variety of cytokines, including interleukin-1␣ (IL-1␣), IL-1␤, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-13, IL-14, tumor necrosis factor-␣, and interferon-␥ (IFN␥) (10, 11) . The cytokine network is complex, with cytokines having both diverse and overlapping functions, including effects that are promoted or inhibited by other cytokines. Cytokine secretion profiles can be considered as either pro-or antiinflammatory or, alternatively, on the basis of the animal model as either T helper cell type 1 (Th1) responses promoting cell-mediated immunity (IL-2 and IFN␥) or T helper cell type 2 (Th2) responses promoting humoral immunity (IL-4, IL-5, IL-6 IL-10, and IL-13) (12) . Despite attempts to classify autoimmune thyroid disease as a classical Th1-or Th2-mediated disease, no clear conclusions can be drawn, and a mixed Th1/Th2 response is seen in both GD and AIH (10) . Cytokines in the thyroid gland also have a role in regulating antigen presentation and lymphocyte trafficking by enhancing the expression of HLA class II and adhesion molecules on thyroid follicular cells (10) . In thyroid-associated ophthalmopathy, cytokines (IL-1␣, tumor necrosis factor-␣, and IFN␥) are pathogenic, promoting inflammation and fibroblast proliferation, leading to the accumulation of glycosaminoglycans (13) . Polymorphisms in genes encoding these crucial immunomodulatory molecules may result in an altered level of expression and hence must be considered important candidate genes for autoimmune disease susceptibility and severity. As cytokines interact functionally, this study examines the contributions of several candidate genes with potential immunoregulatory roles in autoimmune thyroid disease. The candidate genes were selected for investigation if their gene product was likely to be important in the regulation of the cellular or humoral immune response and if a single nucleotide polymorphism within the gene was amenable to genotyping.
IL-1␣ and IL-1␤ are pleiotropic cytokines with primarily proinflammatory effects, including stimulation of IL-2 and IL-6. Both IL-1␣ and IL-1␤ as well as the naturally occurring IL-1 receptor antagonist (IL-1RA) act via the IL-1 receptor 1. Hence, disruption of the balance among IL-1␣, IL-1␤, IL-1RA, and their receptors may result in disease. Polymorphisms of IL-1␣ (position Ϫ889) and IL-1␤ (exon 5, ϩ3962) (14) have been associated with juvenile rheumatoid arthritis (15, 16) and insulin-dependent diabetes mellitus (14, 17) , respectively. Variation in the IL-1RA gene (exon 2) has been associated with a variety of autoimmune disorders (18 -21) , including Graves' disease (22) , although this finding has not been replicated (23) .
IL-4 mediates the humoral immune response, and polymorphisms in IL-4 (position Ϫ590) and its receptor gene (nucleotide 1902) have been associated with atopy (24, 25) . IL-6 is a key inflammatory cytokine, and elevated systemic levels are seen in many conditions, including autoimmune thyroid disease (10) . Promotor region variation of the IL-6 gene has been associated with juvenile rheumatoid arthritis (26) . IL-10 enhances B cell proliferation and an IL-10 polymorphism (position Ϫ1082) has been associated with systemic lupus erythematosus (27) and rheumatoid arthritis (28) . Transforming growth factor-␤ (TGF␤) is another cytokine with important modulatory functions, including an inhibitory role in B cell maturation.
To investigate whether variability in these immunoregulatory genes may influence disease susceptibility or severity, polymorphisms were assessed in a case control association study using a unified method of genotyping.
Subjects and Methods Subjects
The patient cohort comprised 215 Caucasoid patients with autoimmune thyroid disease [135 GD (111 women) and 77 AIH (67 women)] recruited from the endocrinology clinics in Oxford and Sheffield. GD was defined by the presence of hyperthyroidism and diffuse goiter, supported by the presence of either thyroid antibodies (peroxidase and/or thyroglobulin) or thyroid eye disease. AIH was diagnosed by the presence of primary hypothyroidism and positive thyroid antibodies with or without goiter. Information was also obtained on age at diagnosis, size of goiter, presence of other autoimmune disease, and, for GD, severity of ophthalmopathy and relapse rates. The study was approved by the respective local ethics committees, and all subjects gave written informed consent.
The control population comprised 101 Causcasoid cadaveric renal allograft donors. The representative nature of this control population of the general Caucasoid population has previously been shown in HLA genotyping reports (29) .
Genotyping methodology
All genotyping was performed using PCR-sequence specific primers (PCR-SSP). DNA was extracted from 10 mL ethylenediamine tetraacetate blood using the Puregene kit (Gentra Systems, Minneapolis, MN). PCR primers were designed with allele specificity determined by the terminal 3Ј-nucleotide. For detection of two or more closely related polymorphisms within the same gene, forward and reverse allelespecific primers were used (PCR-haplotyping) (30) , thus minimizing the number of PCR reactions and formally identifying the cis/trans orientation of the alleles. Primers and concentrations used for IL-1␣ (Ϫ889t/ c), IL-1␤ (ϩ3962 t/c), IL-4 (Ϫ590c/t), IL-6 (ϩ3247a/g), IL-10 (Ϫ1082a/g, Ϫ819c/t, Ϫ592 c/a), and TGF␤ (Ϫ880g/a, Ϫ509c/t, aa10L/P, aa263T/I) have been previously described (31) . Primers for IL-1␤ (Ϫ511 c/t), IL-1RA, IL-1 receptor 1, and IL-4 receptor are listed in Table 1 . To confirm adequate DNA amplification, all reaction mixes also contained control primers. Further details of the PCR-SSP methodology, including PCR amplification and gel electrophoresis, have been published previously (32) . An example is shown in Fig. 1 .
Statistical analysis
Allele frequencies were compared between the patient groups and the control group using the binomial distribution probability. Genotype frequencies were also compared between the entire patient group and the control group and between the subgroups of GD and AIH compared to the control group using the genotype relative risk method of Lathrop (33) . P values were corrected for the number of independent comparisons of haplotype or allele variants that were made (n ϭ 12) and a corrected P (Pc) value of less than 0.05 was considered significant.
Results
Fifteen polymorphisms in nine genes were analyzed in both the patients and control subjects. The three polymorphisms in the IL-10 gene and the two in the TGF␤ gene (Ϫ800 and Ϫ509) were haplotyped (see Subjects and Methods). All control allele frequencies were in Hardy-Weinberg equilibrium.
The major finding was a striking reduction in the frequency of the IL-4 (Ϫ590) variant t allele in the patients with GD and the overall patient group (GD and AIH) compared to the control group (GD: P exact ϭ 0.00003; Pc ϭ 0.0004; GD and AIH: P exact Ͻ0.00001; Pc Ͻ 0.00001; Table 2 ). For the patients with AIH, a similar trend was seen, but this was not significant when corrected for the number of comparisons made (P exact ϭ 0.006; Pc ϭ 0.07). Genotype analysis showed that the reduction in t allele frequency resulted in fewer IL-4 heterozygote genotypes in the patients with GD compared to controls [P ϭ 0.005; Pc ϭ 0.06; odds ratio (OR), 0.4; 95% confidence interval, 0.2-0.7] which was also seen when all patients were compared with controls (P ϭ 0.0007; Pc ϭ 0.008; OR, 0.4; 95% confidence interval, 0.2-0.7; Table 3 ). Again, a similar tendency was seen for the patients with AIH (P ϭ 0.01; Pc ϭ 0.11), but this was not significant when corrected for the number of observations. Allele and genotype frequencies for the other gene polymorphisms did not differ significantly between the patient and control groups (data not shown, but available from the authors). Further subgroup analysis was performed, and no significant associations of polymorphisms (including the IL-4 Ϫ590 polymorphism) were detected with age of onset of disease, size of goiter, recurrent GD, titer of thyroid peroxidase or thy-roglobulin antibodies, thyroid eye disease, or presence of other autoimmune disease (data not shown).
Discussion
This study provides the first evidence for a genetic association between autoimmune thyroid disease and the IL-4 cytokine gene. This association is due to a decreased prevalence of the variant t allele in the patients with GD, resulting in fewer c/t heterozygote genotypes, compared to controls. In addition, in the AIH group a similar trend was seen, although these results were not significant when multiple comparisons were taken into account.
IL-4 is a key cytokine in immune regulation. It is produced by T cells, mast cells, and eosinophils and causes proliferation of IgE-and IgG-secreting B cells. It also stimulates the expression of HLA class II antigens via STAT6 (signal transducer and activator of transcription-6) (34) and opposes the Th1 cell inflammatory response. Indeed, IL-4 is considered the pivotal cytokine polarizing the immune response toward a Th2 cell response, and although the initial trigger for IL-4 production remains unknown, genetic variation is likely to play a role (35) . The IL-4 polymorphism investigated in this study is a c to t base change in the promotor region of IL-4 at position Ϫ590 (36). This promotor polymorphism appears to be functional, with increased transcriptional activity attributed to the variant allele (24) . Association of this polymorphism (24, 37, 38) and an IL-4 receptor gain of function polymorphism (25) with atopy provides evidence that IL-4 is an important mediator of allergic disease. The mechanism by which IL-4 is involved in the development of autoimmune thyroid disease, particularly GD, requires explanation. T cell activation is believed to be the key event in the initiation of autoimmune thyroid disease (39) , and thus, cytokines are likely to be intimately involved in the process. The patients with autoimmune thyroid disease in our study exhibited a lower prevalence of the variant t allele than the controls, which may reflect a overall lower activity of IL-4. This would favor an inflammatory immune response mediated by Th1 cells. In humans, Th1 cytokines stimulate the production of an IgG1 isotype response (40) , which is the predominant pathogenic TSH receptor autoantibody seen in GD (and sometimes in AIH) (41, 42) . IgG1 isotypes are also prevalent among thyroglobulin and peroxidase antibodies (43, 44) . Hence, in autoimmune thyroid disease, lower IL-4 activity may result in a propensity to develop IgG1 autoantibodies along with polarizing the immune response toward cell-mediated immunity. Supporting this mechanism, IL-4 has been shown to inhibit organspecific autoimmune disease in animals (45, 46) .
For GD, the reduced frequency of the variant t allele was highly significant and associated with small confidence intervals (OR, 0.4; 95% confidence interval, 0.2-0.7). Although not directly comparable, these results are in keeping with previously identified candidate genes for GD, such as HLA DR3 and CTLA-4 (relative risks of 2-5 and 2-3, respectively) (2). It is of interest that a similar trend for an association of the IL-4 polymorphism was seen in the group with AIH compared to the control group. There is some evidence suggesting that the two disorders are related and may represent two ends of a spectrum of autoimmune thyroid disease phenotype. Thus, the two diseases commonly cluster within the same family (47), monozygotic twins are described where one has GD and the other has Hashimoto's thyroiditis (48) , and clinically an individual may fluctuate between GD and AIH. Aspects of the pathogenesis of the two disorders are also related; both are associated with antibodies to thyroid tissue and exhibit some similarities in immune function (10) .
The lack of a significant association after Bonferroni correction for the group with AIH may be because fewer individuals with AIH were genotyped than those with GD (type 1 error).
Although the above explanation supports a pathophysiological mechanism for the association of this IL-4 variant with autoimmune thyroid disease, it is also possible that this association is not due to the IL-4 gene, but to another gene in linkage disequilibrium. The genes for IL-3, IL-5, IL-13, and granulocyte-macrophage colony-stimulating factor are all in close proximity. Of these, IL-13 deserves further attention because of the major role it plays in the cytokine network (34) .
The other cytokine gene polymorphisms evaluated in this study did not reveal any significant associations with autoimmune thyroid disease. Although these negative results exclude any major genetic effect, identifying genes exerting very minor effects or influencing clinical phenotype requires extremely large study cohorts, particularly when several candidate genes are evaluated, and adjustments for multiple comparisons are necessary.
This study has demonstrated a significant association of IL-4 genotype with susceptibility to autoimmune thyroid disease. This suggests that variation in amplification and regulation of immune responses within the thyroid determine clinical disease. However, variation in IL-4 accounts for only part of the abnormal immunoregulatory response seen in autoimmune thyroid disease, and as in other complex diseases, there are likely to be many polymorphic genes, each exerting only a minor effect. This finding is not only of interest to autoimmune thyroid disease, but may also be of relevance to other organ-specific autoimmune diseases. Further examination of polymorphisms in cytokine genes should enhance our understanding of the cytokine network and provide clues to the pathogenesis of particular diseases. clinical data collection, and to the staff at the Churchill Hospital Tissue Typing laboratory for assistance with laboratory aspects of the work.
